Menu

rss

View multiple abstracts by picking relevant boxes and click Get all checked abstracts

Issue information

[Table of contents PDF]

Preface

  • Advances in targeted therapies VII

    • F C Breedveld,
    • J R Kalden,
    • J S Smolen
    Ann Rheum Dis 2005;64:suppl 4 iv1 doi:10.1136/ard.2005.044339

Consensus statement

  • Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

    • D E Furst,
    • F C Breedveld,
    • J R Kalden,
    • J S Smolen,
    • G R Burmester,
    • J W J Bijlsma,
    • M Dougados,
    • P Emery,
    • E C Keystone,
    • L Klareskog,
    • P J Mease
    Ann Rheum Dis 2005;64:suppl 4 iv2-iv14 doi:10.1136/ard.2005.044941

Novel aspects of cellular immunology

  • Stimulation of autoimmunity by toll-like receptor ligands

    • A Limmer,
    • R Ganss,
    • N Garbi,
    • B Arnold,
    • G J Hämmerling
    Ann Rheum Dis 2005;64:suppl 4 iv15-iv17 doi:10.1136/ard.2005.042556

Issues in clinical trial design

  • Biological drug use: US perspectives on indications and monitoring

    • J J Cush
    Ann Rheum Dis 2005;64:suppl 4 iv18-iv23 doi:10.1136/ard.2005.042549

Adverse events with biologics

  • Immunological control of tuberculosis: role of tumour necrosis factor and more

    • S Stenger
    Ann Rheum Dis 2005;64:suppl 4 iv24-iv28 doi:10.1136/ard.2005.042531

  • Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor α

    • K L Winthrop
    Ann Rheum Dis 2005;64:suppl 4 iv29-iv30 doi:10.1136/ard.2005.042390

  • Current state of tumour necrosis factor α blockade in Wegener’s granulomatosis

    • C Mukhtyar,
    • R Luqmani
    Ann Rheum Dis 2005;64:suppl 4 iv31-iv36 doi:10.1136/ard.2005.042416

  • The CORRONA database

    • J Kremer
    Ann Rheum Dis 2005;64:suppl 4 iv37-iv41 doi:10.1136/ard.2005.043497

  • The British Society for Rheumatology Biologics Register

    • K Watson,
    • D Symmons,
    • I Griffiths,
    • A Silman
    Ann Rheum Dis 2005;64:suppl 4 iv42-iv43 doi:10.1136/ard.2005.042499

Joint damage

  • What are the roles of metalloproteinases in cartilage and bone damage?

    • G Murphy,
    • M H Lee
    Ann Rheum Dis 2005;64:suppl 4 iv44-iv47 doi:10.1136/ard.2005.042465

  • Presentation and analysis of radiographic data in clinical trials and observational studies

    • R Landewé,
    • D van der Heijde
    Ann Rheum Dis 2005;64:suppl 4 iv48-iv51 doi:10.1136/ard.2005.042572

  • Are fibroblasts involved in joint destruction?

    • T Pap,
    • I Meinecke,
    • U Müller-Ladner,
    • S Gay
    Ann Rheum Dis 2005;64:suppl 4 iv52-iv54 doi:10.1136/ard.2005.042424

Update on biologicals

  • Update on rituximab

    • R Eisenberg
    Ann Rheum Dis 2005;64:suppl 4 iv55-iv57 doi:10.1136/ard.2005.042648

  • Alefacept for psoriasis and psoriatic arthritis

    • A B Gottlieb
    Ann Rheum Dis 2005;64:suppl 4 iv58-iv60 doi:10.1136/ard.2005.042655

Psoriasis, psoriatic arthritis, ankylosing spondylitis, and other aspects

  • How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?

    • J Sieper,
    • M Rudwaleit
    Ann Rheum Dis 2005;64:suppl 4 iv61-iv64 doi:10.1136/ard.2005.042432

  • Health economics: implications for novel antirheumatic therapies

    • A Kavanaugh
    Ann Rheum Dis 2005;64:suppl 4 iv65-iv69 doi:10.1136/ard.2005.042440

TNF effects and therapeutic response

  • What does tumour necrosis factor excess do to the immune system long term?

    • J Clark,
    • P Vagenas,
    • M Panesar,
    • A P Cope
    Ann Rheum Dis 2005;64:suppl 4 iv70-iv76 doi:10.1136/ard.2005.042523

Molecular basis of the immune response

  • How does B cell depletion therapy work, and how can it be improved?

    • E A Clark,
    • J A Ledbetter
    Ann Rheum Dis 2005;64:suppl 4 iv77-iv80 doi:10.1136/ard.2005.042507

New targets I

  • IKKβ as a target for treatment of inflammation induced bone loss

    • M G Ruocco,
    • M Karin
    Ann Rheum Dis 2005;64:suppl 4 iv81-iv85 doi:10.1136/ard.2005.042721

  • Dendritic cells: potential triggers of autoimmunity and targets for therapy

    • J A Hardin
    Ann Rheum Dis 2005;64:suppl 4 iv86-iv90 doi:10.1136/ard.2005.044560

New targets II

  • Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases

    • N Beyersdorf,
    • T Hanke,
    • T Kerkau,
    • T Hünig
    Ann Rheum Dis 2005;64:suppl 4 iv91-iv95 doi:10.1136/ard.2005.042564

New targets III

  • The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders

    • J M Ilarregui,
    • G A Bianco,
    • M A Toscano,
    • G A Rabinovich
    Ann Rheum Dis 2005;64:suppl 4 iv96-iv103 doi:10.1136/ard.2005.044347

  • Toll-like receptor 2 signalling and inflammation

    • F Y Liew,
    • M Patel,
    • D Xu
    Ann Rheum Dis 2005;64:suppl 4 iv104-iv105 doi:10.1136/ard.2005.042515

Epilogue

  • The 2005 International Symposium on Advances in Targeted Therapies: What have we learned in the 2000s and where are we going?

    • R N Maini
    Ann Rheum Dis 2005;64:suppl 4 iv106-iv108 doi:10.1136/ard.2005.042408

View multiple abstracts by picking relevant boxes and click Get all checked abstracts

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.